北極星藥業-KY (6550.TW) 2025Q2 shows a marked increase in contract liabilities growth (15% – 30%), indicating strong new order acquisition, especially for major product lines. While this bodes well for revenue and profit growth, investors should also examine whether the company has enough capacity and delivery efficiency to avoid bottlenecks.